Ann: 2023 Annual Report to shareholders, page-157

First 157 Last

Share
Profile

Follow
Anydaynow

1,722 Posts.

405

27/04/24

08:19

Post #: 73534311
Share

Originally posted by reggie78: ↑

I have referenced this before, Blackstone's currently has $1 trillion in assets under management, they state they have bought 147 medicines to market at 84% rate of success in phase 3's, with 21 MD's or PHD's on the team.

"We partner with pharmaceutical, biotech and medical technology companies to fund products that address unmet medical needs and have the potential to improve the quality of life for patients around the world.Filling a VoidBlackstone Life Sciences (BXLS) fills a critical void in the industry. While the life sciences are seeing unprecedented innovation driven by rapid advancements in science and technology, there is a lack of funding necessary to bring medicines and healthcare technologies to market. We invest in and partner with pharmaceutical, biotechnology and medical technology companies to help meet this need.Expertise and ScaleBXLS combines clinical, commercial and operational expertise with Blackstone’s knowledge and global network, access to capital, resources and infrastructure. We commit our skill and scale to select, fund and advance what we believe to be the most promising life science products and companies through hands-on involvement and directly applied expertise.Managing RiskWe seek to deliver value for investors by focusing on areas where we can apply our deep clinical and commercial domain expertise. By investing in promising candidates in late-stage development, we aim to make a positive impact on the most people with the lowest clinical risk."

Recent case study last month with Moderna US$750m for future sales milestones and single digit royalties;https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.biospace.com/article/moderna-secures-up-to-750m-in-funding-from-blackstone-to-advance-flu-program/&ved=2ahUKEwjik9WImd-FAxVByzgGHUJeCC8QFnoECBEQAQ&usg=AOvVaw10B09VAeOztPEoCQJu4RNS

Assuming we have same success in remaining phase 2 trails as we have in PMS, the future for Neu under this type of deal with Blackstone or alike offers the best possible out come for patients and shareholders, plenty of cash, firepower with experience in collaboration with our current team, gets drugs to market quickly, Neu in full control, leaves our current cash flow or at least a greater percentage of growing cash flow from DAybue to Neu to develop further indications beyond the current 4.

If our current 4 x 2591 indications have a potential conservative peak sales estimate of US$22bn, bringing another 2-4 into the picture could do the same in the next few years.

I know Jon referenced once that just licensing out 2591 as we have done with Acadia would be a boring type of option, as I have mentioned previously if he quotes that option as boring then TO would be the most boring on any scale especially at a price that is not relative to recent deals like Reta's skyclaves that deal worth US$8bn therefore ours worth US$10bn .......When I think of what would be the most exciting this type of deal with the likes of Blackstone is evidently the most exciting given the opportunity we get to keep our assets for small cost of 10%-20% perhaps, the upside is enormous for Neu with a lot of the risk mitigated.

Expand

I like your thinking Reggie, yes it all hinges on positive P2’s but the upside is enormous for all concerned.

NEU Price at posting: $18.65 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 38 more messages in this thread...

First 157 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $23.11		Change -0.860(3.59%)		Mkt cap ! $2.951B

Open	High	Low	Value	Volume
$23.93	$23.97	$23.05	$23.02M	985.0K

Buyers (Bids)

No.	Vol.	Price($)
3	5083	$23.11

Sellers (Offers)

Price($)	Vol.	No.
$23.25	1026	2

View Market Depth

No.	Vol.	Price($)
2	4539	23.110
1	720	23.090
2	4733	23.050
1	1000	23.010
5	1711	23.000

Price($)	Vol.	No.
23.250	1026	2
23.340	220	1
23.350	500	1
23.360	2401	2
23.370	968	2

Last trade - 16.10pm 28/05/2024 (20 minute delay)


Last $23.22		Change -0.860 ( 3.12 %)
Open	High	Low	Volume
$23.81	$23.94	$23.05	198298
Last updated 15.59pm 28/05/2024 ?

NEU (ASX) Chart

Ann: 2023 Annual Report to shareholders, page-157

Featured News

Downer Wins $600 million water services contract in Queensland

Market Close: ASX dips under with only Staples in the ascendancy

Matador drilling picks up new gold zone in Canada across 1.2km of strike

Winsome sees Adina lithium project's resource rise by a stratospheric 33%

Cleaning up: Why CWY is Wealth Within's Hot Stock tip

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: 2023 Annual Report to shareholders, page-157

Featured News

Top Stories

Downer Wins $600 million water services contract in Queensland

Market Close: ASX dips under with only Staples in the ascendancy

Matador drilling picks up new gold zone in Canada across 1.2km of strike

Winsome sees Adina lithium project's resource rise by a stratospheric 33%

Cleaning up: Why CWY is Wealth Within's Hot Stock tip

Buyers (Bids)

Sellers (Offers)

Featured News